Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Gastroenterology. 2018 Jul 18. pii: S0016-5085(18)34781-4. doi: 10.1053/j.gastro.2018.07.015. [Epub ahead of print]

PMID:
30031138
2.

Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities.

Trzepizur W, Boursier J, Le Vaillant M, Ducluzeau PH, Dubois S, Henni S, Abraham P, Aubé C, Calès P, Gagnadoux F; on the behalf of the METABOL group.

Eur Respir J. 2018 Jun 28;51(6). pii: 1800601. doi: 10.1183/13993003.00601-2018. Print 2018 Jun.

PMID:
29880653
3.

Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification.

Boursier J, Cassinotto C, Hunault G, Shili S, Lebigot J, Lapuyade B, Lannes A, Hiriart JB, Cartier V, Le Bail B, Michalak S, Mouries A, Oberti F, Chermak F, Fouchard-Hubert I, Cales P, Aube C, de Ledinghen V.

Clin Gastroenterol Hepatol. 2018 May 9. pii: S1542-3565(18)30470-1. doi: 10.1016/j.cgh.2018.04.062. [Epub ahead of print]

PMID:
29753082
4.

A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement.

Bastard C, Miette V, Calès P, Stefanescu H, Festi D, Sandrin L.

Ultrasound Med Biol. 2018 Aug;44(8):1616-1626. doi: 10.1016/j.ultrasmedbio.2018.03.028. Epub 2018 May 3.

PMID:
29731186
5.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
6.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034. [Epub ahead of print]

PMID:
29663511
7.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.

PMID:
29653647
8.

A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis.

Calès P, Boursier J, Oberti F, Moal V, Fouchard Hubert I, Bertrais S, Hunault G, Rousselet MC; multicentric groups (SNIFF, ANRS HC 23).

Hepatol Commun. 2018 Mar 5;2(4):455-466. doi: 10.1002/hep4.1161. eCollection 2018 Apr.

9.

Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.

Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, Michalak S, Bonnafous S, Michielsen P, Oberti F, Iannelli A, Van Gaal L, Patouraux S, Blanchet O, Verrijken A, Gual P, Rousselet MC, Driessen A, Hunault G, Bertrais S, Tran A, Calès P, Francque S.

Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25.

PMID:
29577364
10.

Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes".

Boursier J, de Ledinghen V, Leroy V, Calès P.

J Hepatol. 2018 Mar;68(3):605-606. doi: 10.1016/j.jhep.2017.09.022. Epub 2017 Oct 4. No abstract available.

PMID:
28987517
11.

The noninvasive diagnosis of esophageal varices and its application in clinical practice.

Pateu E, Oberti F, Calès P.

Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):6-16. doi: 10.1016/j.clinre.2017.07.006. Epub 2017 Sep 1. Review.

PMID:
28870440
12.

A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

Ducancelle A, Leroy V, Vergniol J, Sturm N, Le Bail B, Zarski JP, Nguyen Khac E, Salmon D, de Ledinghen V, Calès P.

J Clin Gastroenterol. 2017 Aug;51(7):639-649. doi: 10.1097/MCG.0000000000000788.

PMID:
28692443
13.

Large oesophageal varice screening by a sequential algorithm using a cirrhosis blood test and optionally capsule endoscopy.

Calès P, Sacher-Huvelin S, Valla D, Bureau C, Olivier A, Oberti F, Boursier J, Galmiche JP; multicenter group VO-VCO.

Liver Int. 2018 Jan;38(1):84-93. doi: 10.1111/liv.13497. Epub 2017 Jul 7.

PMID:
28622450
14.

Assessment of renal hemodynamic toxicity of fluid challenge with 0.9% NaCl compared to balanced crystalloid (PlasmaLyte®) in a rat model with severe sepsis.

Olivier PY, Beloncle F, Seegers V, Tabka M, Renou de La Bourdonnaye M, Mercat A, Cales P, Henrion D, Radermacher P, Piquilloud L, Lerolle N, Asfar P.

Ann Intensive Care. 2017 Dec;7(1):66. doi: 10.1186/s13613-017-0286-1. Epub 2017 Jun 14.

15.

Editorial: combining elastography with blood test for fibrosis assessment in chronic hepatitis C - authors' reply.

Calès P, Boursier J.

Aliment Pharmacol Ther. 2017 May;45(9):1276-1277. doi: 10.1111/apt.14032. No abstract available.

PMID:
28370034
16.

Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C.

Chindamo MC, Boursier J, Luiz RR, Fouchard-Hubert I, Pannain VL, de Araújo Neto JM, Coelho HS, de Mello Perez R, Calès P, Villela-Nogueira CA.

World J Hepatol. 2017 Feb 28;9(6):310-317. doi: 10.4254/wjh.v9.i6.310.

17.

Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?

Calès P, Boursier J, Lebigot J, de Ledinghen V, Aubé C, Hubert I, Oberti F.

Aliment Pharmacol Ther. 2017 Apr;45(7):991-1003. doi: 10.1111/apt.13954. Epub 2017 Feb 6.

PMID:
28164327
18.

A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.

Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, Lannes A, Bertrais S, Oberti F, Fouchard-Hubert I, Calès P.

J Hepatol. 2017 Jun;66(6):1158-1165. doi: 10.1016/j.jhep.2017.01.003. Epub 2017 Jan 12.

PMID:
28088581
19.

Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests.

Bertrais S, Boursier J, Ducancelle A, Oberti F, Fouchard-Hubert I, Moal V, Calès P.

J Gastroenterol Hepatol. 2017 Jun;32(6):1240-1249. doi: 10.1111/jgh.13668.

PMID:
27897323
20.

Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity.

Ducancelle A, Pivert A, Bertrais S, Boursier J, Balan V, Veillon P, le Guillou-Guillemette H, Thibault V, Castelain S, Roquebert B, Coste-Burel M, Mackiewicz V, Schvoerer E, Larrat S, Maylin S, Alain S, Loustaud-Ratti V, Gordien E, Gozlan J, Brodard V, Chevaliez S, Calès P, Lunel-Fabiani F.

J Gastroenterol Hepatol. 2016 Oct;31(10):1750-1756. doi: 10.1111/jgh.13338.

PMID:
26992056
21.

Association Between Severity of Obstructive Sleep Apnea and Blood Markers of Liver Injury.

Trzepizur W, Boursier J, Mansour Y, Le Vaillant M, Chollet S, Pigeanne T, Bizieux-Thaminy A, Humeau MP, Alizon C, Goupil F, Meslier N, Priou P, Calès P, Gagnadoux F; Institut de Recherche en Santé Respiratoire des Pays de la Loire Sleep Cohort Group.

Clin Gastroenterol Hepatol. 2016 Nov;14(11):1657-1661. doi: 10.1016/j.cgh.2016.04.037. Epub 2016 May 5.

PMID:
27155555
22.

Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients.

Lainé F, Ruivard M, Loustaud-Ratti V, Bonnet F, Calès P, Bardou-Jacquet E, Sacher-Huvelin S, Causse X, Beusnel C, Renault A, Bellissant E, Deugnier Y; Study Group.

Hepatology. 2017 Feb;65(2):465-474. doi: 10.1002/hep.28856. Epub 2016 Nov 10.

23.

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.

Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Gastroenterology. 2017 Jan;152(1):142-156.e2. doi: 10.1053/j.gastro.2016.09.009. Epub 2016 Sep 15.

PMID:
27641509
24.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).

Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.

Hepatology. 2016 Oct;64(4):1136-47. doi: 10.1002/hep.28702. Epub 2016 Aug 4.

25.

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Calès P, de Lédinghen V.

J Hepatol. 2016 Sep;65(3):570-8. doi: 10.1016/j.jhep.2016.04.023. Epub 2016 May 2.

PMID:
27151181
26.

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.

Cassinotto C, Boursier J, de Lédinghen V, Lebigot J, Lapuyade B, Cales P, Hiriart JB, Michalak S, Bail BL, Cartier V, Mouries A, Oberti F, Fouchard-Hubert I, Vergniol J, Aubé C.

Hepatology. 2016 Jun;63(6):1817-27. doi: 10.1002/hep.28394. Epub 2016 Jan 22.

PMID:
26659452
27.

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.

Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM.

Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.

28.

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).

Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Trinchet JC, Moreau R, Roudot-Thoraval F; ANRS CO12 CirVir and Microcir Groups.

Gut. 2017 Feb;66(2):330-341. doi: 10.1136/gutjnl-2015-310275. Epub 2015 Oct 28.

PMID:
26511797
29.

Automated morphometry provides accurate and reproducible virtual staging of liver fibrosis in chronic hepatitis C.

Calès P, Chaigneau J, Hunault G, Michalak S, Cavaro-Menard C, Fasquel JB, Bertrais S, Rousselet MC.

J Pathol Inform. 2015 May 28;6:20. doi: 10.4103/2153-3539.157782. eCollection 2015.

30.

Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests.

Guéchot J, Boursier J, de Ledinghen V, Poynard T, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group and/or AFEF.

Clin Chem Lab Med. 2015 Jul;53(8):1135-7. doi: 10.1515/cclm-2015-0241. No abstract available.

31.

Screening of esophageal varices by esophageal capsule endoscopy: results of a French multicenter prospective study.

Sacher-Huvelin S, Calès P, Bureau C, Valla D, Vinel JP, Duburque C, Attar A, Archambeaud I, Benamouzig R, Gaudric M, Luet D, Couzigou P, Planche L, Galmiche JP, Coron E.

Endoscopy. 2015 Jun;47(6):486-92. doi: 10.1055/s-0034-1391393. Epub 2015 Mar 2.

PMID:
25730284
32.

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; ANRS CO12 CirVir Group.

Hepatology. 2015 Sep;62(3):737-50. doi: 10.1002/hep.27743. Epub 2015 Mar 20.

PMID:
25678021
33.

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.

Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GL, Friedrich-Rust M, Fraquelli M, Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P; ARDENT group; AFEF.

J Hepatol. 2015 Apr;62(4):807-15. doi: 10.1016/j.jhep.2014.10.042. Epub 2014 Nov 5.

PMID:
25450206
34.

IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells.

Miot C, Beaumont E, Duluc D, Le Guillou-Guillemette H, Preisser L, Garo E, Blanchard S, Hubert Fouchard I, Créminon C, Lamourette P, Fremaux I, Calès P, Lunel-Fabiani F, Boursier J, Braum O, Fickenscher H, Roingeard P, Delneste Y, Jeannin P.

Gut. 2015 Sep;64(9):1466-75. doi: 10.1136/gutjnl-2013-306604. Epub 2014 Sep 2.

PMID:
25183206
35.

Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding.

Thabut D, Rudler M, Dib N, Carbonell N, Mathurin P, Saliba F, Mallet A, Massard J, Bernard-Chabert B, Oberti F, Cales P, Golmard JL, Bureau C; French Club for the Study of Portal Hypertension (CFEHTP).

Hepatology. 2015 Mar;61(3):1024-32. doi: 10.1002/hep.27407. Epub 2015 Jan 30.

PMID:
25179168
36.

IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells.

Preisser L, Miot C, Le Guillou-Guillemette H, Beaumont E, Foucher ED, Garo E, Blanchard S, Frémaux I, Croué A, Fouchard I, Lunel-Fabiani F, Boursier J, Roingeard P, Calès P, Delneste Y, Jeannin P.

Hepatology. 2014 Dec;60(6):1879-90. doi: 10.1002/hep.27328. Epub 2014 Oct 29.

PMID:
25066464
37.

Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P.

Aliment Pharmacol Ther. 2014 Jul;40(2):178-88. doi: 10.1111/apt.12813. Epub 2014 Jun 2.

38.

Cirrhosis Diagnosis and Liver Fibrosis Staging: Transient Elastometry Versus Cirrhosis Blood Test.

Calès P, Boursier J, Oberti F, Bardou D, Zarski JP, de Lédinghen V; Multicentric Group.

J Clin Gastroenterol. 2015 Jul;49(6):512-9. doi: 10.1097/MCG.0000000000000138.

PMID:
24828359
39.

Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C.

Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, Chermak F, Hubert IF, Merrouche W, Oberti F, de Lédinghen V, Calès P.

Hepatology. 2014 Jul;60(1):65-76. doi: 10.1002/hep.27069.

PMID:
24519328
40.

Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C.

Sandrini J, Boursier J, Chaigneau J, Sturm N, Zarski JP, Le Bail B, de Ledinghen V, Calès P, Rousselet MC.

Mod Pathol. 2014 Jul;27(7):1035-45. doi: 10.1038/modpathol.2013.225. Epub 2014 Jan 3.

41.

Improved fibrosis staging by elastometry and blood test in chronic hepatitis C.

Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F; ANRS HC EP 23 Fibrostar Study.

Liver Int. 2014 Jul;34(6):907-17. doi: 10.1111/liv.12327. Epub 2013 Oct 16.

PMID:
24102852
42.

Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

Calès P, de Ledinghen V, Guéchot J.

Ann Intern Med. 2013 Sep 3;159(5):371-2. doi: 10.7326/0003-4819-159-5-201309030-00020. No abstract available.

PMID:
24026328
43.

AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations.

Guéchot J, Boisson RC, Zarski JP, Sturm N, Calès P, Lasnier E; ANRS HCEP 23 Fibrostar Group.

Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):467-72. doi: 10.1016/j.clinre.2013.07.003. Epub 2013 Aug 8.

PMID:
23932706
44.

Renal macro- and microcirculation autoregulatory capacity during early sepsis and norepinephrine infusion in rats.

Burban M, Hamel JF, Tabka M, de La Bourdonnaye MR, Duveau A, Mercat A, Calès P, Asfar P, Lerolle N.

Crit Care. 2013 Jul 12;17(4):R139. doi: 10.1186/cc12818.

45.

Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C.

Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR.

J Gastroenterol. 2014 Mar;49(3):527-37. doi: 10.1007/s00535-013-0819-9. Epub 2013 May 17.

PMID:
23681425
46.

Metastatic hepatocellular carcinoma: when surgery and successive palliative treatments lead to remission.

Brochard C, Hamy A, Michalak S, Aubé C, Picquet J, Nebout N, Caroli-Bosc FX, Oberti F, Calès P, Boursier J.

Clin Res Hepatol Gastroenterol. 2014 Feb;38(1):e19-22. doi: 10.1016/j.clinre.2013.02.006. Epub 2013 Apr 20.

PMID:
23608740
47.

MRI measurement of liver fat content predicts the metabolic syndrome.

Ducluzeau PH, Boursier J, Bertrais S, Dubois S, Gauthier A, Rohmer V, Gagnadoux F, Leftheriotis G, Cales P, Andriantsitohaina R, Roullier V, Aubé C.

Diabetes Metab. 2013 Sep;39(4):314-21. doi: 10.1016/j.diabet.2013.01.007. Epub 2013 Mar 21.

PMID:
23523139
48.

Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice.

Boursier J, Rousselet MC, Aubé C, Calès P.

Expert Opin Med Diagn. 2012 Sep;6(5):381-94. doi: 10.1517/17530059.2012.691878. Epub 2012 May 25.

PMID:
23480804
49.

A major new step in non-invasive evaluation of portal hypertension: elastography.

Bureau C, Di Martino V, Calès P.

Liver Int. 2013 Jan;33(1):4-6. doi: 10.1111/liv.12008. Epub 2012 Nov 1. No abstract available.

PMID:
23121438
50.

Determination of reliability criteria for liver stiffness evaluation by transient elastography.

Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P; Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies.

Hepatology. 2013 Mar;57(3):1182-91. doi: 10.1002/hep.25993. Epub 2013 Feb 4.

PMID:
22899556

Supplemental Content

Support Center